These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34931119)

  • 41. Structure-Based Development of SARS-CoV-2 Spike Interactors.
    Squeglia F; Romano M; Esposito L; Barra G; Campiglia P; Sala M; Scala MC; Ruggiero A; Berisio R
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes.
    Dutta S; Panthi B; Chandra A
    J Phys Chem B; 2022 Jul; 126(29):5375-5389. PubMed ID: 35833966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 Spike mutations modify the interaction between virus Spike and human ACE2 receptors.
    Mishra PM; Anjum F; Uversky VN; Nandi CK
    Biochem Biophys Res Commun; 2022 Sep; 620():8-14. PubMed ID: 35772213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants.
    Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sönnerborg A; Byrareddy SN; Singh K
    Comput Struct Biotechnol J; 2021; 19():3799-3809. PubMed ID: 34188776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex.
    Peka M; Balatsky V
    Future Virol; 2023 Mar; ():. PubMed ID: 37064325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
    Ibrahim IM; Elfiky AA; Elgohary AM
    Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study.
    Yang Y; Zhang Y; Qu Y; Zhang C; Liu XW; Zhao M; Mu Y; Li W
    Nanoscale; 2021 May; 13(20):9364-9370. PubMed ID: 33999091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zn
    Pelucelli A; Peana M; Orzeł B; Piasta K; Gumienna-Kontecka E; Medici S; Zoroddu MA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Consequences of Variation in SARS-CoV-2 B.1.1.7.
    Ostrov DA
    J Cell Immunol; 2021; 3(2):103-108. PubMed ID: 33969357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational Design of Miniprotein Inhibitors Targeting SARS-CoV-2 Spike Protein.
    Wu J; Zhang J; Zhang HX
    Langmuir; 2022 Aug; 38(34):10690-10703. PubMed ID: 35984970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
    Solanki K; Rajpoot S; Kumar A; J Zhang KY; Ohishi T; Hirani N; Wadhonkar K; Patidar P; Pan Q; Baig MS
    Future Virol; 2022 Jul; ():. PubMed ID: 35935449
    [No Abstract]   [Full Text] [Related]  

  • 55. The interaction of the severe acute respiratory syndrome coronavirus 2 spike protein with drug-inhibited angiotensin converting enzyme 2 studied by molecular dynamics simulation.
    Nami B; Ghanaeian A; Ghanaeian K; Houri R; Nami N; Ghasemi-Dizgah A; Caluseriu O
    J Hypertens; 2021 Aug; 39(8):1705-1716. PubMed ID: 34188005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of S477N mutation in the molecular behavior of SARS-CoV-2 spike protein: An in-silico perspective.
    Mondeali M; Etemadi A; Barkhordari K; Mobini Kesheh M; Shavandi S; Bahavar A; Tabatabaie FH; Mahmoudi Gomari M; Modarressi MH
    J Cell Biochem; 2023 Feb; 124(2):308-319. PubMed ID: 36609701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
    Borkotoky S; Dey D; Hazarika Z
    Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
    Luan B; Wang H; Huynh T
    FEBS Lett; 2021 May; 595(10):1454-1461. PubMed ID: 33728680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design.
    Huang SH; Chen YT; Lin XY; Ly YY; Lien ST; Chen PH; Wang CT; Wu SC; Chen CC; Lin CY
    Sci Rep; 2023 Aug; 13(1):13468. PubMed ID: 37596329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19.
    Ahmadvand M; Barough MS; Hashemi ZS; Sanati H; Abbasvandi F; Yunesian M; Majidzadeh-A K; Makarem J; Aghayan HR; Abedini A; Ghavamzadeh A; Forooshani RS
    Pilot Feasibility Stud; 2023 Aug; 9(1):137. PubMed ID: 37542307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.